These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8746925)

  • 1. Evaluation of a point-of-care testing product for drugs of abuse; testing site is a key variable.
    Kranzler HR; Stone J; McLaughlin L
    Drug Alcohol Depend; 1995 Nov; 40(1):55-62. PubMed ID: 8746925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of eight commercial on-site screening devices for drugs-of-abuse testing.
    Leino A; Saarimies J; Grönholm M; Lillsunde P
    Scand J Clin Lab Invest; 2001 Jul; 61(4):325-31. PubMed ID: 11465347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting cocaine and opiates in urine: comparing three commercial assays.
    Schilling RF; Bidassie B; El-Bassel N
    J Psychoactive Drugs; 1999; 31(3):305-13. PubMed ID: 10533978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the accuracy of on-site multi-analyte drug testing devices in the determination of the prevalence of illicit drugs in drivers.
    Buchan BJ; Walsh JM; Leaverton PE
    J Forensic Sci; 1998 Mar; 43(2):395-9. PubMed ID: 9544550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over- and underreporting of recent drug use in subjects entering an inpatient detoxification unit.
    Zullino DF; Krenz S; Eap CB; Benguettat D; Khan R
    Eur J Med Res; 2008 Jan; 13(1):15-20. PubMed ID: 18226992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity testing of the EZ-SCREEN cannabinoid test.
    Jenkins AJ; Mills LC; Darwin WD; Huestis MA; Cone EJ; Mitchell JM
    J Anal Toxicol; 1993 Sep; 17(5):292-8. PubMed ID: 8107464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing.
    Huestis MA; Cone EJ; Wong CJ; Umbricht A; Preston KL
    J Anal Toxicol; 2000 Oct; 24(7):509-21. PubMed ID: 11043653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the EZ-SCREEN enzyme immunoassay test for detection of cocaine and marijuana metabolites in urine specimens.
    Schwartz RH; Bogema S; Thorne MM
    Pediatr Emerg Care; 1990 Jun; 6(2):147-9. PubMed ID: 2196539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiple-site laboratory evaluation of three on-site urinalysis drug-testing devices.
    Crouch DJ; Frank JF; Farrell LJ; Karsch HM; Klaunig JE
    J Anal Toxicol; 1998 Oct; 22(6):493-502. PubMed ID: 9788525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration distribution of the marijuana metabolite Delta9-tetrahydrocannabinol-9-carboxylic acid and the cocaine metabolite benzoylecgonine in the department of defense urine drug-testing program.
    Jemionek JF; Copley CL; Smith ML; Past MR
    J Anal Toxicol; 2008; 32(6):408-16. PubMed ID: 18652746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of random and postaccident urine drug tests in southern Indiana coal miners.
    Price JW
    J Addict Med; 2012 Dec; 6(4):253-7. PubMed ID: 22895464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential risk of patient misclassification using a point-of-care testing kit for urine drugs of abuse.
    Matthews JC; Wassif WS
    Br J Biomed Sci; 2010; 67(4):218-20. PubMed ID: 21294451
    [No Abstract]   [Full Text] [Related]  

  • 14. Urinary excretion profiles of 11-nor-9-carboxy-Delta9-tetrahydrocannabinol: a Delta9-THC-COOH to creatinine ratio study #2.
    Fraser AD; Worth D
    Forensic Sci Int; 2003 Apr; 133(1-2):26-31. PubMed ID: 12742686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytic performance of immunoassays for drugs of abuse below established cutoff values.
    Luzzi VI; Saunders AN; Koenig JW; Turk J; Lo SF; Garg UC; Dietzen DJ
    Clin Chem; 2004 Apr; 50(4):717-22. PubMed ID: 14764642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical evaluation of four on-site oral fluid drug testing devices.
    Vanstechelman S; Isalberti C; Van der Linden T; Pil K; Legrand SA; Verstraete AG
    J Anal Toxicol; 2012 Mar; 36(2):136-40. PubMed ID: 22337784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of three commercial tests for buprenorphine screening in urine.
    Leino A; Loo BM
    Ann Clin Biochem; 2007 Nov; 44(Pt 6):563-5. PubMed ID: 17961313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of extraction techniques for drugs of abuse in urine.
    Wilson JF; Smith BL; Toseland PA; Watson ID; Williams J; Thomson AH; Capps NE; Sweeney G; Sandle LN;
    Forensic Sci Int; 2001 Jun; 119(1):23-7. PubMed ID: 11348790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A field evaluation of five on-site drug-testing devices.
    Crouch DJ; Hersch RK; Cook RF; Frank JF; Walsh JM
    J Anal Toxicol; 2002 Oct; 26(7):493-9. PubMed ID: 12423006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ONTRAK TESTCUP: a novel, on-site, multi-analyte screen for the detection of abused drugs.
    Towt J; Tsai SC; Hernandez MR; Klimov AD; Kravec CV; Rouse SL; Subuhi HS; Twarowska B; Salamone SJ
    J Anal Toxicol; 1995 Oct; 19(6):504-10. PubMed ID: 8926746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.